RICHARD BROOKS: Open Payments
NPI 1457761314 · ABERDEEN, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,498 in 68 payments from 13 companies in 2025. Trend: 2023 $961 · 2024 $723 · 2025 $1,498
Food & beverage: $1,397Education: $101
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $255 |
| Janssen Pharmaceuticals, Inc | 12 | $227 |
| ABBVIE INC. | 8 | $177 |
| Alkermes, Inc. | 7 | $158 |
| Teva Pharmaceuticals USA, Inc. | 3 | $158 |
| E.R. Squibb & Sons, L.L.C. | 9 | $157 |
| Supernus Pharmaceuticals, Inc. | 5 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $89 |
| Otsuka America Pharmaceutical, Inc. | 2 | $59 |
| Bausch Health US, LLC | 2 | $33 |
Products named: INGREZZA, INVEGA SUSTENNA, VRAYLAR, COBENFY, Qelbree, ARISTADA, TRINTELLIX, REXULTI.
Industry payments across WA — which companies pay providers there.
